You searched for "clinics"
Belfast briefing: Retina Day roundup from the RCOphth 2024 Annual Congress
Belfast hosted this year’s Royal College of Ophthalmologists’ (RCOphth) Annual Congress, a meeting dedicated to sharing advances, knowledge and clinical practice points in ophthalmic care. This article summarises selected talks by medical and surgical retina specialists during the Retina Subspecialty...
Opening the AI ‘black box’ for glaucoma
Artificial intelligence (AI) models show great promise for glaucoma detection using retinal images, but their ‘black box’ nature is a major barrier to clinical adoption. Clinicians are often hesitant to trust a diagnosis without understanding its reasoning. This paper provides...Keep calm and cut the carbon – improving sustainability in ophthalmology
As I dump my tenth pair of gloves into a non-recyclable clinical waste bin; dispose of another handful of plastic minims; or print another wad of single-sided discharge paperwork after a cataract surgery, the inconvenient truth of how these seemingly...It’s Friday, I’m In Love: Pete’s Hidden Curriculum Part 3
“When you’re in love, it’s the most glorious two-and-a-half days of your life.” - Richard Lewis [1]. The good news is that we are over the hump now and past the most depressing day of the year, which is known...The Wachter Review
Professor Robert Wachter (pronounced Wokter) is well known in the NHS IT sector. In late 2015 Jeremy Hunt announced he had tasked Dr Wachter to lead a review of the digital future of the NHS. The resulting Wachter Review was...Glaucoma UK announces winners of the 2025 ‘Excellence in Glaucoma Care Award’
Glaucoma UK is delighted to announce the winners of this year's Excellence in Glaucoma Care Awards – Patrick (Paddy) Gunn from Manchester and Alex Gage Family Optometrists in Sheffield. This annual award celebrates individuals or teams who have made remarkable...
Licence to save: a UK survey of anti-VEGF use for the eye
This comment article highlights the controversy that exists in the choice for anti-VEGF drugs used for treatment of macular oedema and wet age-related macular degeneration (AMD). Two existing licensed drugs for macular oedema are ranibizumab (Lucentis) and aflibercept (Eylea). A...
